Phase 2a Trial Of MEM 3454 In Alzheimer's Disease.
Alzheimer's Donation
Donate Online Now
.
Memory Pharmaceuticals Corp. announced the dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the company's lead nicotinic alpha-7 receptor partial agonist, in Alzheimer's disease. The trial is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in subjects with mild to moderate Alzheimer's disease. MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the CNS. Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. MEM 3454 is the Company's lead drug candidate from its nicotinic alpha-7 agonist program. Memory Pharmaceuticals is developing MEM 3454 as potential therapy for Alzheimer's disease and is considering developing the compound as a treatment for schizophrenia as well as other disorders that affect cognition.
"MEM 3454 showed promising cognitive effects in its Phase 1 clinical trial and we're excited about evaluating its efficacy in a disease setting," said Stephen R. Murray, M.D., Ph.D., Vice President of Clinical Development. "We now have two drug candidates, with two distinct mechanisms of action, in clinical trials for the treatment of Alzheimer's disease, and we expect to report top-line results from both trials in the fourth quarter of this year."
The trial will enroll approximately 80 subjects with mild to moderate Alzheimer's disease at multiple sites in the United States. Subjects will be randomized to receive 5 mg, 15 mg or 50 mg of MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effect of MEM 3454 using the Quality of Episodic Secondary Memory (QESM) factor score from the Cognitive Drug Research (CDR) battery. Secondary objectives include assessing the safety, tolerability, and pharmacokinetics of multiple doses of MEM 3454 and the drug candidate's effect on additional psychometric test items from the CDR battery and the Alzheimer's Disease Assessment Scale -- Cognitive subscale (ADAS - cog). Under the terms of the Company's nicotinic alpha-7 agonist collaboration with Roche, the Company leads the development of MEM 3454 through Phase 2a clinical trials, and following the completion of these trials, Roche has the right to obtain an exclusive license to MEM 3454. Roche maintains this right through the development process by making payments to Memory Pharmaceuticals upon its achievement of certain predefined development milestones. For additional information, please visit our website at http://www.memorypharma.com.
Alzheimer's Donation
Donate Online Now
.
Memory Pharmaceuticals Corp. announced the dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the company's lead nicotinic alpha-7 receptor partial agonist, in Alzheimer's disease. The trial is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in subjects with mild to moderate Alzheimer's disease. MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the CNS. Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. MEM 3454 is the Company's lead drug candidate from its nicotinic alpha-7 agonist program. Memory Pharmaceuticals is developing MEM 3454 as potential therapy for Alzheimer's disease and is considering developing the compound as a treatment for schizophrenia as well as other disorders that affect cognition.
"MEM 3454 showed promising cognitive effects in its Phase 1 clinical trial and we're excited about evaluating its efficacy in a disease setting," said Stephen R. Murray, M.D., Ph.D., Vice President of Clinical Development. "We now have two drug candidates, with two distinct mechanisms of action, in clinical trials for the treatment of Alzheimer's disease, and we expect to report top-line results from both trials in the fourth quarter of this year."
The trial will enroll approximately 80 subjects with mild to moderate Alzheimer's disease at multiple sites in the United States. Subjects will be randomized to receive 5 mg, 15 mg or 50 mg of MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effect of MEM 3454 using the Quality of Episodic Secondary Memory (QESM) factor score from the Cognitive Drug Research (CDR) battery. Secondary objectives include assessing the safety, tolerability, and pharmacokinetics of multiple doses of MEM 3454 and the drug candidate's effect on additional psychometric test items from the CDR battery and the Alzheimer's Disease Assessment Scale -- Cognitive subscale (ADAS - cog). Under the terms of the Company's nicotinic alpha-7 agonist collaboration with Roche, the Company leads the development of MEM 3454 through Phase 2a clinical trials, and following the completion of these trials, Roche has the right to obtain an exclusive license to MEM 3454. Roche maintains this right through the development process by making payments to Memory Pharmaceuticals upon its achievement of certain predefined development milestones. For additional information, please visit our website at http://www.memorypharma.com.
posted by Valery Yermalitsky at
5:39 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home